103 - References

References

Schizophrenia and related psychoses CHAPTER 1 In practice, penfluridol is usually started at a dose of 20mg and increased to a maximum of 40mg after assessment. Steady-state levels are effectively reached after 2–3 weeks. Monitoring includes investigations of renal and hepatic function, changes in cardiometabolic parameter such as lipids, blood glucose, ECG and general adverse effect screening. Other antipsychotics which may be suitable for once-weekly oral administration include pimozide, aripiprazole and cariprazine.12 References

1. Janssen PA, et al. The pharmacology of penfluridol (R 16341) a new potent and orally long-­acting neuroleptic drug. Eur J Pharmacol 1970; 11:139–154.
2. Cooper SF, et al. Penfluridol steady-­state kinetics in psychiatric patients. Clin Pharmacol Ther 1975; 18:325–329.
3. Migdalof BH, et al. Penfluridol: a neuroleptic drug designed for long duration of action. Drug Metab Rev 1979; 9:281–299.
4. Soares BG, et al. Penfluridol for schizophrenia. Cochrane Database Syst Rev 2006; (2):CD002923.
5. Iqbal MJ, et al. A long term comparative trial of penfluridol and fluphenazine decanoate in schizophrenic outpatients. J Clin Psychiatry 1978; 39:375–379.
6. Quitkin F, et al. Long-­acting oral vs injectable antipsychotic drugs in schizophrenics: a one-­year double-­blind comparison in multiple episode schizophrenics. Arch Gen Psychiatry 1978; 35:889–892.
7. van der Lee APM, et al. The impact of antipsychotic formulations on time to medication discontinuation in patients with schizophrenia: a Dutch registry-­based retrospective cohort study. CNS Drugs 2021; 35:451–460.
8. Dunnett D, et al. Evaluation of the effectiveness and acceptability of the long-­acting oral antipsychotic penfluridol: illustrative case series. J Psychopharmacol 2021; 36:223–231.
9. van Praag HM, et al. Controlled trial of penfluridol in acute psychosis. Br Med J 1971; 4:710–713.
10. Shopsin B, et al. Penfluridol: an open phase III study in acute newly admitted hospitalized schizophrenic patients. Psychopharmacology (Berl) 1977; 55:157–164.
11. Munitz H, et al. Loading: a beneficial therapeutic effect using an oral long-­acting drug, Penfluridol (SEMAP). A pilot study. Isr J Psychiatry Relat Sci 1986; 23:215–220.
12. Brissos S, et  al. Weekly supervised administration of oral antipsychotics: an alternative to long-­acting injections? CNS Drugs 2022; 36:315–325.
13. Bhattacharyya R, et al. Resurgence of penfluridol: merits and demerits. Eastern J Psychiatry 2015; 18:23–29.
14. Ashraf-­Uz-­Zaman M, et al. Analogs of penfluridol as chemotherapeutic agents with reduced central nervous system activity. Bioorg Med Chem Lett 2018; 28:3652–3657.